Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Lightweight High-Performance Polymer Composite for Automotive Applications.

Polymers

Volpe V, Lanzillo S, Affinita G, Villacci B, Macchiarolo I, Pantani R.
PMID: 30960310
Polymers (Basel). 2019 Feb 13;11(2). doi: 10.3390/polym11020326.

The automotive industry needs to produce plastic products with high dimensional accuracy and reduced weight, and this need drives the research toward less conventional industrial processes. The material that was adopted in this work is a glass-fiber-reinforced polyamide 66...

Cite
Volpe V, Lanzillo S, Affinita G, et al. Lightweight High-Performance Polymer Composite for Automotive Applications. Polymers (Basel). 2019;11(2)doi: 10.3390/polym11020326.
Volpe, V., Lanzillo, S., Affinita, G., Villacci, B., Macchiarolo, I., & Pantani, R. (2019). Lightweight High-Performance Polymer Composite for Automotive Applications. Polymers, 11(2), . https://doi.org/10.3390/polym11020326
Volpe, Valentina, et al. "Lightweight High-Performance Polymer Composite for Automotive Applications." Polymers vol. 11,2 (2019). doi: https://doi.org/10.3390/polym11020326
Volpe V, Lanzillo S, Affinita G, Villacci B, Macchiarolo I, Pantani R. Lightweight High-Performance Polymer Composite for Automotive Applications. Polymers (Basel). 2019 Feb 13;11(2). doi: 10.3390/polym11020326. PMID: 30960310; PMCID: PMC6419205.
Copy Download .nbib Format: NLM
Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.

Frontiers in pediatrics

Bonvini P, Rossi E, Zin A, Manicone M, Vidotto R, Facchinetti A, Tombolan L, Affinita MC, Santoro L, Zamarchi R, Bisogno G.
PMID: 33996693
Front Pediatr. 2021 Apr 29;9:652583. doi: 10.3389/fped.2021.652583. eCollection 2021.

Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis is generally good. For children with unresectable or metastatic tumors, however, outcome is particularly severe, limited also by the...

Cite
Bonvini P, Rossi E, Zin A, et al. Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Front Pediatr. 2021;9:652583doi: 10.3389/fped.2021.652583.
Bonvini, P., Rossi, E., Zin, A., Manicone, M., Vidotto, R., Facchinetti, A., Tombolan, L., Affinita, M. C., Santoro, L., Zamarchi, R., & Bisogno, G. (2021). Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Frontiers in pediatrics, 9652583. https://doi.org/10.3389/fped.2021.652583
Bonvini, Paolo, et al. "Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor." Frontiers in pediatrics vol. 9 (2021): 652583. doi: https://doi.org/10.3389/fped.2021.652583
Bonvini P, Rossi E, Zin A, Manicone M, Vidotto R, Facchinetti A, Tombolan L, Affinita MC, Santoro L, Zamarchi R, Bisogno G. Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Front Pediatr. 2021 Apr 29;9:652583. doi: 10.3389/fped.2021.652583. eCollection 2021. PMID: 33996693; PMCID: PMC8116882.
Copy Download .nbib Format: NLM
Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review.

Journal of pediatric hematology/oncology

Reggiani G, Affinita MC, Dall'Igna P, Virgone C, Sorbara S, Bisogno G.
PMID: 33323880
J Pediatr Hematol Oncol. 2021 Nov 01;43(8):288-293. doi: 10.1097/MPH.0000000000002033.

Pancreatoblastoma (PB) is a tumor typically seen in childhood. Despite its rarity, there are some internationally agreed recommendations for its first-line treatment, but very little is known about the management of relapse. We reviewed the literature on the treatment...

Cite
Reggiani G, Affinita MC, Dall'Igna P, et al. Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. J Pediatr Hematol Oncol. 2021;43(8):288-293doi: 10.1097/MPH.0000000000002033.
Reggiani, G., Affinita, M. C., Dall'Igna, P., Virgone, C., Sorbara, S., & Bisogno, G. (2021). Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. Journal of pediatric hematology/oncology, 43(8), 288-293. https://doi.org/10.1097/MPH.0000000000002033
Reggiani, Giulia, et al. "Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review." Journal of pediatric hematology/oncology vol. 43,8 (2021): 288-293. doi: https://doi.org/10.1097/MPH.0000000000002033
Reggiani G, Affinita MC, Dall'Igna P, Virgone C, Sorbara S, Bisogno G. Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. J Pediatr Hematol Oncol. 2021 Nov 01;43(8):288-293. doi: 10.1097/MPH.0000000000002033. PMID: 33323880.
Copy Download .nbib Format: NLM
Role of centers with different patient volumes in the management of rhabdomyosarcoma. An analysis by the Italian Pediatric Soft Tissue Sarcoma Committee.

Pediatric blood & cancer

Bisogno G, Congiu G, Affinita MC, Milano GM, Zanetti I, Coppadoro B, Manzitti C, Basso E, Tamburini A, Melchionda F, Cellini M, Pericoli R, D'Angelo P, Cataldo AD, De Leonardis F, Rabusin M, De Corti F, Zin A, Alaggio R, Scarzello G, Ferrari A.
PMID: 34260145
Pediatr Blood Cancer. 2021 Dec;68(12):e29234. doi: 10.1002/pbc.29234. Epub 2021 Jul 14.

PROCEDURE: The survival of children with rhabdomyosarcoma (RMS) has gradually improved as a result of the adoption of multidisciplinary treatments. Dedicated skills and facilities are indispensable and more readily available at reference centers. In this study, we examined the...

Cite
Bisogno G, Congiu G, Affinita MC, et al. Role of centers with different patient volumes in the management of rhabdomyosarcoma. An analysis by the Italian Pediatric Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2021;68(12):e29234doi: 10.1002/pbc.29234.
Bisogno, G., Congiu, G., Affinita, M. C., Milano, G. M., Zanetti, I., Coppadoro, B., Manzitti, C., Basso, E., Tamburini, A., Melchionda, F., Cellini, M., Pericoli, R., D'Angelo, P., Cataldo, A. D., De Leonardis, F., Rabusin, M., De Corti, F., Zin, A., Alaggio, R., Scarzello, G., & Ferrari, A. (2021). Role of centers with different patient volumes in the management of rhabdomyosarcoma. An analysis by the Italian Pediatric Soft Tissue Sarcoma Committee. Pediatric blood & cancer, 68(12), e29234. https://doi.org/10.1002/pbc.29234
Bisogno, Gianni, et al. "Role of centers with different patient volumes in the management of rhabdomyosarcoma. An analysis by the Italian Pediatric Soft Tissue Sarcoma Committee." Pediatric blood & cancer vol. 68,12 (2021): e29234. doi: https://doi.org/10.1002/pbc.29234
Bisogno G, Congiu G, Affinita MC, Milano GM, Zanetti I, Coppadoro B, Manzitti C, Basso E, Tamburini A, Melchionda F, Cellini M, Pericoli R, D'Angelo P, Cataldo AD, De Leonardis F, Rabusin M, De Corti F, Zin A, Alaggio R, Scarzello G, Ferrari A. Role of centers with different patient volumes in the management of rhabdomyosarcoma. An analysis by the Italian Pediatric Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 2021 Dec;68(12):e29234. doi: 10.1002/pbc.29234. Epub 2021 Jul 14. PMID: 34260145.
Copy Download .nbib Format: NLM
Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared.

Diagnostics (Basel, Switzerland)

Rossi E, Zin A, Facchinetti A, Poggiana C, Tombolan L, Affinita MC, Bonvini P, Santoro L, Schiavi F, Bisogno G, Zamarchi R.
PMID: 33053902
Diagnostics (Basel). 2020 Oct 12;10(10). doi: 10.3390/diagnostics10100810.

Pediatric renal cancer is rare, and robust evidence for treatment recommendations is lacking. In the perspective of personalized medicine, clinicians need new biomarkers to improve risk stratification and patients' follow-up. Herein, we analyzed some liquid biopsy tools, which have...

Cite
Rossi E, Zin A, Facchinetti A, et al. Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. Diagnostics (Basel). 2020;10(10)doi: 10.3390/diagnostics10100810.
Rossi, E., Zin, A., Facchinetti, A., Poggiana, C., Tombolan, L., Affinita, M. C., Bonvini, P., Santoro, L., Schiavi, F., Bisogno, G., & Zamarchi, R. (2020). Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. Diagnostics (Basel, Switzerland), 10(10), . https://doi.org/10.3390/diagnostics10100810
Rossi, Elisabetta, et al. "Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared." Diagnostics (Basel, Switzerland) vol. 10,10 (2020). doi: https://doi.org/10.3390/diagnostics10100810
Rossi E, Zin A, Facchinetti A, Poggiana C, Tombolan L, Affinita MC, Bonvini P, Santoro L, Schiavi F, Bisogno G, Zamarchi R. Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. Diagnostics (Basel). 2020 Oct 12;10(10). doi: 10.3390/diagnostics10100810. PMID: 33053902; PMCID: PMC7599903.
Copy Download .nbib Format: NLM
High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.

Cancer cell international

Ramaglia M, D'Angelo V, Iannotta A, Di Pinto D, Pota E, Affinita MC, Donofrio V, Errico ME, Lombardi A, Indolfi C, Casale F, Caraglia M.
PMID: 27471434
Cancer Cell Int. 2016 Jul 28;16:59. doi: 10.1186/s12935-016-0338-x. eCollection 2016.

BACKGROUND: Enhancer of Zeste Drosophila Homologue 2 (EZH2) is a key regulator of transcription as a member of polycomb repressive complex 2 (PRC2) which exerts repression of downstream genes and is correlated to invasiveness and progression of different tumours....

Cite
Ramaglia M, D'Angelo V, Iannotta A, et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int. 2016;16:59doi: 10.1186/s12935-016-0338-x.
Ramaglia, M., D'Angelo, V., Iannotta, A., Di Pinto, D., Pota, E., Affinita, M. C., Donofrio, V., Errico, M. E., Lombardi, A., Indolfi, C., Casale, F., & Caraglia, M. (2016). High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer cell international, 1659. https://doi.org/10.1186/s12935-016-0338-x
Ramaglia, Maria, et al. "High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas." Cancer cell international vol. 16 (2016): 59. doi: https://doi.org/10.1186/s12935-016-0338-x
Ramaglia M, D'Angelo V, Iannotta A, Di Pinto D, Pota E, Affinita MC, Donofrio V, Errico ME, Lombardi A, Indolfi C, Casale F, Caraglia M. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int. 2016 Jul 28;16:59. doi: 10.1186/s12935-016-0338-x. eCollection 2016. PMID: 27471434; PMCID: PMC4964052.
Copy Download .nbib Format: NLM
Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.

Frontiers in pediatrics

Bonvini P, Rossi E, Zin A, Manicone M, Vidotto R, Facchinetti A, Tombolan L, Affinita MC, Santoro L, Zamarchi R, Bisogno G.
PMID: 33996693
Front Pediatr. 2021 Apr 29;9:652583. doi: 10.3389/fped.2021.652583. eCollection 2021.

Inflammatory myofibroblastic tumors (IMTs) are locally aggressive malignancies occurring at various sites. Surgery is the mainstay of treatment and prognosis is generally good. For children with unresectable or metastatic tumors, however, outcome is particularly severe, limited also by the...

Cite
Bonvini P, Rossi E, Zin A, et al. Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Front Pediatr. 2021;9:652583doi: 10.3389/fped.2021.652583.
Bonvini, P., Rossi, E., Zin, A., Manicone, M., Vidotto, R., Facchinetti, A., Tombolan, L., Affinita, M. C., Santoro, L., Zamarchi, R., & Bisogno, G. (2021). Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Frontiers in pediatrics, 9652583. https://doi.org/10.3389/fped.2021.652583
Bonvini, Paolo, et al. "Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor." Frontiers in pediatrics vol. 9 (2021): 652583. doi: https://doi.org/10.3389/fped.2021.652583
Bonvini P, Rossi E, Zin A, Manicone M, Vidotto R, Facchinetti A, Tombolan L, Affinita MC, Santoro L, Zamarchi R, Bisogno G. Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. Front Pediatr. 2021 Apr 29;9:652583. doi: 10.3389/fped.2021.652583. eCollection 2021. PMID: 33996693; PMCID: PMC8116882.
Copy Download .nbib Format: NLM
Laparoscopic splenectomy with selective intra-corporeal ligation of splenic hilar vessels for high grade splenic injury - video vignette.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Birindelli A, Segalini E, Affinita A, Tugnoli G, Di Saverio S.
PMID: 29224238
Colorectal Dis. 2017 Dec 10; doi: 10.1111/codi.13988. Epub 2017 Dec 10.

A 59-year-old hemodynamically stable female is admitted following a domestic fall with blunt left sided thoraco-abdominal trauma. She lived alone and had multiple comorbidities including hepatitis C virus positive splenomegaly, chronic psychosis with a history of opioid and alcohol...

Cite
Birindelli A, Segalini E, Affinita A, et al. Laparoscopic splenectomy with selective intra-corporeal ligation of splenic hilar vessels for high grade splenic injury - video vignette. Colorectal Dis. 2017;doi: 10.1111/codi.13988.
Birindelli, A., Segalini, E., Affinita, A., Tugnoli, G., & Di Saverio, S. (2017). Laparoscopic splenectomy with selective intra-corporeal ligation of splenic hilar vessels for high grade splenic injury - video vignette. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, . https://doi.org/10.1111/codi.13988
Birindelli, Arianna, et al. "Laparoscopic splenectomy with selective intra-corporeal ligation of splenic hilar vessels for high grade splenic injury - video vignette." Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland vol. (2017). doi: https://doi.org/10.1111/codi.13988
Birindelli A, Segalini E, Affinita A, Tugnoli G, Di Saverio S. Laparoscopic splenectomy with selective intra-corporeal ligation of splenic hilar vessels for high grade splenic injury - video vignette. Colorectal Dis. 2017 Dec 10; doi: 10.1111/codi.13988. Epub 2017 Dec 10. PMID: 29224238.
Copy Download .nbib Format: NLM
Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas.

Pediatric blood & cancer

Bisogno G, Ferrari A, Tagarelli A, Sorbara S, Chiaravalli S, Poli E, Scarzello G, De Corti F, Casanova M, Affinita MC.
PMID: 33694265
Pediatr Blood Cancer. 2021 Jul;68(7):e28951. doi: 10.1002/pbc.28951. Epub 2021 Mar 10.

BACKGROUND: Irinotecan is a drug active against pediatric sarcomas with a toxicity profile that theoretically allows for its association with more myelotoxic drugs. We examined the feasibility of a dose-density strategy integrating irinotecan in standard chemotherapy regimens for patients...

Cite
Bisogno G, Ferrari A, Tagarelli A, et al. Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas. Pediatr Blood Cancer. 2021;68(7):e28951doi: 10.1002/pbc.28951.
Bisogno, G., Ferrari, A., Tagarelli, A., Sorbara, S., Chiaravalli, S., Poli, E., Scarzello, G., De Corti, F., Casanova, M., & Affinita, M. C. (2021). Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas. Pediatric blood & cancer, 68(7), e28951. https://doi.org/10.1002/pbc.28951
Bisogno, Gianni, et al. "Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas." Pediatric blood & cancer vol. 68,7 (2021): e28951. doi: https://doi.org/10.1002/pbc.28951
Bisogno G, Ferrari A, Tagarelli A, Sorbara S, Chiaravalli S, Poli E, Scarzello G, De Corti F, Casanova M, Affinita MC. Integrating irinotecan in standard chemotherapy: A novel dose-density combination for high-risk pediatric sarcomas. Pediatr Blood Cancer. 2021 Jul;68(7):e28951. doi: 10.1002/pbc.28951. Epub 2021 Mar 10. PMID: 33694265.
Copy Download .nbib Format: NLM
Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review.

Journal of pediatric hematology/oncology

Reggiani G, Affinita MC, Dall'Igna P, Virgone C, Sorbara S, Bisogno G.
PMID: 33323880
J Pediatr Hematol Oncol. 2021 Nov 01;43(8):288-293. doi: 10.1097/MPH.0000000000002033.

Pancreatoblastoma (PB) is a tumor typically seen in childhood. Despite its rarity, there are some internationally agreed recommendations for its first-line treatment, but very little is known about the management of relapse. We reviewed the literature on the treatment...

Cite
Reggiani G, Affinita MC, Dall'Igna P, et al. Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. J Pediatr Hematol Oncol. 2021;43(8):288-293doi: 10.1097/MPH.0000000000002033.
Reggiani, G., Affinita, M. C., Dall'Igna, P., Virgone, C., Sorbara, S., & Bisogno, G. (2021). Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. Journal of pediatric hematology/oncology, 43(8), 288-293. https://doi.org/10.1097/MPH.0000000000002033
Reggiani, Giulia, et al. "Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review." Journal of pediatric hematology/oncology vol. 43,8 (2021): 288-293. doi: https://doi.org/10.1097/MPH.0000000000002033
Reggiani G, Affinita MC, Dall'Igna P, Virgone C, Sorbara S, Bisogno G. Treatment Strategies for Children With Relapsed Pancreatoblastoma: A Literature Review. J Pediatr Hematol Oncol. 2021 Nov 01;43(8):288-293. doi: 10.1097/MPH.0000000000002033. PMID: 33323880.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries